
|Videos|May 6, 2021
A look at real-world trial data replication outcomes from IRIS Registry data
Author(s)David Hutton, OT Staff Reports
Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.
Advertisement
Theodore Leng, MD, medical advisor at Verana Health and director of clinical translational research, Byers Eye Institute, Stanford University School of Medicine, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," in which the first replications using real-world data of a phase 3 trial was utilized, during the virtual 2021 ARVO meeting.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Q&A: Evolving approaches to geographic atrophy management
2
Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
3
Rates of retinal layer thinning predict visual field progression in glaucoma
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5














































